December 1-2, 2018 - New Orleans, LA, USA
Abstracts were accepted from July 1 - September 30, 2018
Abstract content should be restricted to basic and translational research directed toward elucidation of normal function, characterization of benign disease states of the pelvic viscera and pelvic floor, and/or therapeutic development and/or characterization of therapeutic approaches for treatment of benign disease states of the pelvic viscera and pelvic floor. Abstract submissions will be accepted until September 30th, 2018.
Abstract submission should not include results that have been accepted for publication, but may include data that has been presented elsewhere. "Poster Only" and "Oral Presentation" abstract acceptances will be limited to one per designated presenter (i.e. designated presenters may present one Oral Presentation and/or one Poster Presentation. This rule is intended to limit meeting "domination" by any single investigator or laboratory. Abstracts may be submitted by both current members and non-members.
Abstract acceptance/rejection notices will be delivered by October 15th, 2018. Designated presenters must register for the Meeting by November 15th, 2018, if their abstracts have been accepted, or the abstract will be withdrawn from acceptance. If multiple abstracts are accepted for a single Member or Non-member Meeting Registrant for either presentation category, that individual will be contacted to select which abstract they prefer to present.
Physiology and Pharmacology
Muscle and Organ Function
Models and Methods in Pelvic Research
Neurotrauma and Pelvic Function
Novel Therapies/Diagnostics for Pelvic Disorders